Incorporated in the year 16th April 1990 Caplin Point Laboratories was promoted by P C Partheeban T Palanisamy S Karunakaran S Jayaraman and B A Ahmed. The company manufactures pharmaceutical formulations in the form of tablets ointments and capsules liquid orals and oral powders. As on 31 March 2019 the Company has four subsidiaries viz Caplin Steriles Limited Argus Salud Pharma LLP Caplin Point Far East Limited - Hongkong and Caplin Point Laboratories Colombia SAS- Colombia. The company came out with a public issue in Nov.'94 and expanded its production capacity by setting up a new unit to manufacture its range of products at Pondicherry. The company has retained its SSI status even after the expansion and thus will be out of the purview of the DPCO. During 1993-94 Triwin (a partnership firm) was merged with Caplin Point. The company entered into a technical agreement with American Remedies and Concord Laboratories US for specific products with a 30% buyback arrangement. It also imports bio-technological products to market them in India.The company has established a trading branch in Nairobi Kenya to sell its products in East Africa. It has also established a warehouse in Miami US by entering into a marketing tie-up with Lockett Medical Corporation US.During the year 2015 the Company has invested a sum of Rs 89.10 Lakhs in Argus Salud Pharma LLP. Consequently the Company's share in LLP has increased to 99.90% in Argus Salud Pharma LLP.In October 2016 the Company had subdivided the shares from the face value of Rs 10/- to Rs 2/- and upon sub-division the members were issued five equity shares of Rs 2/- each in lieu of one equity share of Rs 10/- each. After sub-division the paid up capital of Rs151100000 was sub- divided into 75550000 equity shares of Rs 2/- each.As on 31 March 2018 the Company has three subsidiaries viz Argus Salud Pharma LLP Caplin Point Far East Limited - Hongkong and Caplin Point Laboratories Colombia SAS- Colombia.During the year 2019 the Company transferred its regulated markets injectable business which inter-alia includes US FDA approved injectable plant and Department of Science and Industrial Research (DSIR) recognised R& D Units CP4 and CP 5 to Caplin Steriles Limited a Wholly Owned Subsidiary Company for which the approval was granted by the members of the Company by way of Special Resolution through Postal Ballot on December 31 2018.In FY2019 the Company attracted investments in Caplin Steriles Limited from Eight Roads Ventures India Ill LP and F-Prime Capital Partners Life Sciences Fund VI LP in the form of Compulsorily Convertible Preference Shares (CCPS) which shall be converted into equity shares of Caplin Steriles Limited based on the agreed terms.During FY 2019 the Company formed a Joint Venture Hainan Jointown Caplinpoint Pharmaceutical Company Limited in Hainan Province of China which will be focusing on international trade of medicines and establishment of marketing team in India and China for export of composite formulations to customers in China India Europe and Latin America.